Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Rhea-AI Summary

Immuron (Nasdaq:IMRN) received a Flash Report from Emerging Growth Research on April 22, 2026, which maintained a Buy-Extended rating and raised the 12-month price target to $4.00 from $3.90.

Key facts: global product revenue of AUD $1.5 million in 3Q FY2026 (+16% YoY); Australia revenue +15% YoY; U.S. +1% YoY (AUD basis); Canada +82% QoQ; third product launched in Australia Dec 2025; IMM-529 cleared by FDA to proceed to Phase 2; Emerging Growth values enterprise at ~$33.3 million using a 6.22x EV/Revenue multiple.

Positive

• Global revenue AUD $1.5M in 3Q FY2026 (+16% YoY)
• Canada revenue +82% QoQ (sequential growth)
• IMM-529 received FDA clearance to proceed into Phase 2
• Third commercial product launched in Australia Dec 2025
• Emerging Growth raised 12-month price target to $4.00

Negative

• U.S. revenue growth only +1% YoY on an AUD basis
• Absolute quarterly revenue remains small at AUD $1.5M
• Company seeks partners to advance late-stage development, indicating funding or execution dependence

News Market Reaction – IMRN

-3.38%

3 alerts

-3.38% News Effect

-$249K Valuation Impact

$7.11M Market Cap

0.9x Rel. Volume

On the day this news was published, IMRN declined 3.38%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $249K from the company's valuation, bringing the market cap to $7.11M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

12-month price target: $4.00 Prior price target: $3.90 Reference share price: $0.9268 +5 more

8 metrics

12-month price target $4.00 Raised from $3.90 in Emerging Growth Research flash report

Prior price target $3.90 Previous 12-month target before latest flash report

Reference share price $0.9268 IMRN share price as of April 21, 2026 cited in report

Q3 product revenue AUD $1.5 million Global product revenue for 3Q FY2026

Revenue growth YoY 16% Year-over-year increase in 3Q FY2026 global product revenue

Australia revenue growth 15% Year-over-year Q3 growth in Australia (in AUD)

Canada QoQ growth 82% Sequential quarter-over-quarter revenue increase in Canada

EV/Revenue multiple 6.22x Peer group EV/Revenue multiple used to derive valuation

Market Reality Check

Price: $0.8813 Vol: Pre‑news volume of 10,273...

low vol

$0.8813 Last Close

Volume Pre‑news volume of 10,273 is light at 0.33x the 20‑day average of 31,099, indicating limited positioning ahead of the report. low

Technical Shares at 0.9268 were trading below the 200-day MA of 1.39 and sat 61.22% under the 52‑week high of 2.39, despite the bullish target hike.

Peers on Argus

IMRN’s pre‑news move of -3.25% contrasted with mixed peers: XTLB was up 1.23%, w...

2 Up

IMRN’s pre‑news move of -3.25% contrasted with mixed peers: XTLB was up 1.23%, while ADAP, APM, PHGE, and PHIO were modestly down. Momentum scans showed SNSE up 4.149999842047691% and APM up 4.490000009536743% without same‑day news, and the sector flag remained false, pointing to a stock‑specific setup.

Historical Context

5 past events · Latest: Apr 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 17	Q3 sales update	Positive	+13.3%	Reported Q3 sales of AUD$1.5M, up 16% year-over-year across key regions.
Mar 05	Flash update & results	Positive	+4.5%	H1 FY26 results, revenue growth, cash raised via ATM, and FDA trial progress.
Mar 05	Conference presentation	Neutral	+4.5%	CEO presentation at Coffee Microcaps Conference with updated investor materials.
Feb 25	HY26 results reset	Positive	+17.1%	HY26 revenue growth, cash position, and strategic reset focused on partnerships.
Jan 22	Flash update & target	Positive	+1.4%	Flash update with H1 FY26 revenue growth and reaffirmed Buy-Extended rating.

Pattern Detected

Recent news with sales growth, strategy updates, and analyst flash reports often coincided with positive 24h moves, suggesting the stock has historically responded favorably to fundamental and research‑driven catalysts.

Recent Company History

Over the last few months, IMRN has repeatedly highlighted revenue growth and strategic progress. A Jan 22 flash update maintained a $3.50 target alongside AUD$4.2M H1 revenue. HY26 results on Feb 25 showed AUD$4.2M sales and AUD$10.0M cash, while a Mar 5 flash update reiterated growth and narrowed losses. The Apr 17 Q3 sales release reported AUD$1.5M revenue, up 16%. Today’s higher $4.00 target builds directly on that same growth and pipeline story.

Market Pulse Summary

This announcement from Emerging Growth Research maintains a Buy-Extended stance on IMRN and raises t...

Analysis

This announcement from Emerging Growth Research maintains a Buy-Extended stance on IMRN and raises the 12‑month price target to $4.00, citing Q3 FY2026 product revenue of AUD$1.5M with 16% year‑over‑year growth. The report emphasizes expanding Travelan sales in Australia, the U.S., and Canada, plus FDA‑cleared Phase 2 plans for IMM‑529. Investors may focus on sustained revenue growth, clinical milestones, and partnering progress for IMM‑124E and IMM‑529 as key markers.

Key Terms

ev/revenue, enterprise valuation, phase 2 clinical trials, clostridioides difficile

4 terms

ev/revenue financial

"Based on an updated peer group EV/Revenue multiple of 6.22x, Emerging Growth Research"

EV/Revenue is a valuation ratio that compares a company’s total market value (including debt and cash) to its annual sales. Investors use it to judge how much they are paying for each dollar of revenue, which is helpful when profits vary or are negative — like comparing how much you’d pay for different shops based on their yearly receipts rather than their recent profit. Lower values often suggest cheaper relative valuation, higher values imply pricier expectations.

enterprise valuation financial

"EV/Revenue multiple of 6.22x, Emerging Growth Research derives an enterprise valuation of"

Enterprise valuation is an estimate of what an entire business is worth to a buyer, combining the value of its equity with obligations like debt while subtracting cash that would come with the company. Think of it as the full purchase price someone would pay for a house after accounting for the mortgage and any cash in the bank; investors use it to compare companies fairly, assess takeover prices, and judge whether a stock is cheap or expensive on an apples‑to‑apples basis.

phase 2 clinical trials medical

"IMM-529 for Clostridioides difficile (C. difficile) infections, with FDA clearance to proceed into Phase 2 clinical trials"

Phase 2 clinical trials are mid-stage tests of a new treatment in a larger group of patients to assess whether it works and to further evaluate safety and dosing. Think of it like a more serious test drive after basic checks: success suggests the treatment has real potential and justifies larger, more expensive late-stage trials, which can increase a drug developer’s value to investors, while failure often leads to sharp declines in outlook.

clostridioides difficile medical

"IMM-529 for Clostridioides difficile (C. difficile) infections, with FDA clearance"

Clostridioides difficile is a bacterium that can overgrow in the gut after antibiotics and cause severe, sometimes recurring, diarrhea and inflammation; it spreads easily in hospitals and care facilities. Investors care because it drives demand for diagnostics, new drugs, vaccines and infection-control services, can raise hospital costs and liability risks, and creates a steady market for companies offering prevention or treatment—like a persistent malfunction that keeps repair business steady.

AI-generated analysis. Not financial advice.

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026.

The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.

Key Highlights:

• Double-Digit Revenue Growth: Immuron reported global product revenue of AUD $1.5 million for 3Q FY2026, representing a 16% year-over-year increase. Growth was primarily driven by increased sales of Travelan^® across Australia and the United States.

• Strong Core Market Performance: Year-over-year revenue growth in Australia and the U.S. reached 15% and 1%, respectively (in AUD), with stronger underlying U.S. growth when measured in USD due to foreign exchange impacts.

• Rapid Expansion in Canada: While still a smaller market, Canadian revenue demonstrated strong sequential growth, increasing 82% quarter-over-quarter, supported by ongoing brand awareness initiatives.

• Revenue-Generating Commercial Products: Immuron continues to generate revenue from its marketed products in Australia, the U.S., and Canada, helping offset clinical development costs. A third product was launched in Australia in December 2025.

• Promising Clinical Pipeline: The Company is advancing two key candidates:

  • IMM-124E (Travelan^®) for travelers' diarrhea

  • IMM-529 for Clostridioides difficile (C. difficile) infections, with FDA clearance to proceed into Phase 2 clinical trials

• Strategic Partnering Opportunities: Immuron is actively seeking partners to advance both IMM-124E and IMM-529 through later-stage development.

• Compelling Valuation: Based on an updated peer group EV/Revenue multiple of 6.22x, Emerging Growth Research derives an enterprise valuation of approximately $33.3 million, supporting the increased $4.00 price target.

For a copy of the full Flash Report, please visit:

https://emerginggrowth.com/wp-content/uploads/2026/04/Immuron-Flash-Report-2026-04-22.pdf

Or

https://www.emerginggrowth.com/profile/imrn/ (on the right side of the page as you scroll down)

About Immuron
Immuron Limited is a commercial and clinical-stage biopharmaceutical company focused on developing oral immunotherapies for the treatment of gastrointestinal infections. The Company's proprietary platform utilizes polyclonal antibodies derived from hyperimmune bovine colostrum. Immuron markets products in Australia, the United States, and Canada, while advancing a pipeline targeting infectious diseases with significant unmet medical needs.

About Emerging Growth Research
Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing research coverage - including Flash Reports on material developments - to enhance transparency and broaden market awareness for companies participating in the Emerging Growth Conference platform.

Contact:
Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.com

Forward-Looking Statements
This press release contains forward-looking statements concerning business operations, financial performance, and future expectations. These statements are subject to risks and uncertainties, and actual results may differ materially from those projected. Investors are encouraged to review all risk factors and disclosures before making investment decisions.

SOURCE: Immuron Limited

View the original press release on ACCESS Newswire

FAQ

What 12-month price target did Emerging Growth Research set for Immuron (IMRN) on April 22, 2026?

Emerging Growth Research set a $4.00 12-month price target for IMRN. According to Emerging Growth Research, this reflects an increase from $3.90 and implies meaningful upside versus the April 21, 2026 share price of $0.9268.

How much revenue did Immuron (IMRN) report for 3Q FY2026 and what was the growth rate?

Immuron reported AUD $1.5 million in global product revenue for 3Q FY2026, a +16% YoY increase. According to Emerging Growth Research, growth was driven mainly by Travelan sales in Australia and the U.S.

What clinical progress did Immuron (IMRN) disclose regarding IMM-529 on April 22, 2026?

IMM-529 received FDA clearance to proceed into Phase 2 clinical trials. According to Emerging Growth Research, this clearance advances IMM-529 toward later-stage development for C. difficile infections.

How did Immuron's regional performance compare in 3Q FY2026 for Australia, the U.S., and Canada?

Australia revenue grew +15% YoY, U.S. grew +1% YoY (AUD basis), and Canada rose +82% QoQ. According to Emerging Growth Research, Canada showed rapid sequential expansion from brand awareness efforts.

What valuation and multiple did Emerging Growth Research use to support the new IMRN price target?

Emerging Growth Research applied a 6.22x EV/Revenue multiple to derive an enterprise value of ~$33.3 million. According to Emerging Growth Research, that valuation underpins the $4.00 price target.

Does Immuron (IMRN) have commercially generating products and recent launches?

Yes. Immuron generates revenue from marketed products in Australia, the U.S., and Canada and launched a third product in Australia in December 2025. According to Emerging Growth Research, commercial sales help offset clinical development costs.